SCOR Valuation

Is SCRP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SCRP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SCRP (€23.8) is trading below our estimate of fair value (€72.37)

Significantly Below Fair Value: SCRP is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SCRP?

Key metric: As SCRP is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SCRP. This is calculated by dividing SCRP's market cap by their current revenue.
What is SCRP's PS Ratio?
PS Ratio0.3x
Sales€15.62b
Market Cap€4.32b

Price to Sales Ratio vs Peers

How does SCRP's PS Ratio compare to its peers?

The above table shows the PS ratio for SCRP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.8x
CRE Conduit Holdings
1.4x14.4%UK£752.7m
HSX Hiscox
1.2x11.4%UK£3.5b
PHNX Phoenix Group Holdings
0.2x-27.6%UK£5.0b
DLG Direct Line Insurance Group
0.6x0.7%UK£2.0b
SCRP SCOR
0.3x9.5%€4.3b

Price-To-Sales vs Peers: SCRP is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (0.8x).


Price to Sales Ratio vs Industry

How does SCRP's PS Ratio compare vs other companies in the GB Insurance Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
RQIH R&Q Insurance Holdings
0.001xn/aUS$360.20k
No more companies available in this PS range
No. of Companies3PS00.61.21.82.43+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: SCRP is good value based on its Price-To-Sales Ratio (0.3x) compared to the European Insurance industry average (1x).


Price to Sales Ratio vs Fair Ratio

What is SCRP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SCRP PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SCRP's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SCRP forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€23.80
€25.99
+9.2%
16.6%€36.00€19.00n/a15
Nov ’25€19.85
€25.59
+28.9%
21.7%€37.00€18.00n/a15
Oct ’25€19.75
€25.65
+29.9%
22.1%€37.00€18.00n/a15
Sep ’25€19.22
€26.05
+35.6%
22.4%€37.00€18.00n/a15
Aug ’25€19.08
€27.89
+46.2%
19.3%€37.00€19.00n/a15
Jul ’25n/a
€33.75
0%
9.3%€39.00€27.00n/a15
Jun ’25€26.38
€33.96
+28.7%
8.1%€39.00€28.00n/a15
May ’25n/a
€34.79
0%
9.2%€40.00€28.00n/a15
Apr ’25n/a
€34.47
0%
9.5%€40.00€28.00n/a15
Mar ’25n/a
€32.99
0%
7.0%€37.00€27.00n/a16
Feb ’25n/a
€32.96
0%
7.1%€37.00€27.00n/a16
Jan ’25n/a
€32.91
0%
8.1%€37.00€27.00n/a16
Dec ’24n/a
€32.91
0%
8.1%€37.00€27.00n/a16
Nov ’24€27.69
€31.97
+15.5%
12.9%€37.00€23.50€19.8516
Oct ’24€30.01
€31.28
+4.3%
11.9%€36.40€23.50€19.7516
Sep ’24n/a
€30.68
0%
11.4%€36.00€23.50€19.2216
Aug ’24€27.09
€30.68
+13.3%
11.4%€36.00€23.50€19.0816
Jul ’24€26.93
€27.87
+3.5%
14.9%€35.00€20.00n/a17
Jun ’24€24.51
€27.75
+13.2%
14.5%€34.00€20.00€26.3817
May ’24n/a
€26.63
0%
11.9%€32.00€20.00n/a17
Apr ’24€20.86
€26.69
+27.9%
12.1%€32.00€20.00n/a17
Mar ’24€23.16
€25.68
+10.9%
16.0%€32.00€17.50n/a16
Feb ’24€22.52
€25.43
+12.9%
15.9%€32.00€17.50n/a16
Jan ’24€22.19
€23.76
+7.1%
17.7%€30.00€16.50n/a16
Dec ’23€18.80
€23.73
+26.2%
17.8%€30.00€16.50n/a16
Nov ’23€14.46
€23.60
+63.3%
18.5%€30.00€16.00€27.6916

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies